{"url_path":"/sec/cbio/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-040051-index.html","accession_number":"0001628280-26-040051","cik":"0001253689","ticker":"CBIO","issuer_name":"CRESCENT BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-040051-index.html","primary_entity_key":"0001253689","primary_entity_name":"CRESCENT BIOPHARMA, INC."},"word_count":552,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders.\n\nOn June 2, 2026, Crescent Biopharma, Inc. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). At the close of business on April 7, 2026, the record date for the Annual Meeting (the “Record Date”), 27,571,935 ordinary shares, par value $0.001 per share (“Ordinary Shares”), were issued and outstanding, and 2,890 Series A non-voting convertible preferred shares, par value $0.001 per share (“Series A Preferred Shares”), were issued and outstanding. Each Ordinary Share was entitled to one vote per share for the election of Susan Moran, M.D., MSCE and one vote on each of proposals 3, 4 and 5. The holders of each Series A Preferred Share were entitled to 1,000 votes per share, voting as a separate class for the election of Jonathan Violin, Ph.D. and voting together with the holders of Ordinary Shares as a single class for the election of Susan Moran, M.D., MSCE, and were not entitled to vote on any other proposal. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which was described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2026.\n\nProposal No. 1A and Proposal No. 1B - Election of two Class II directors to serve until the Company’s 2029 Annual General Meeting of Shareholders and until their respective successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal.\n\nVotes FORVotes WITHHELDBroker Non-Votes\n\nJonathan Violin, Ph.D. (Proposal No. 1A)2,890,00000\n\nSusan Moran, M.D., MSCE (Proposal No. 1B)21,401,136136,0562,403,515\n\nProposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nVotes FORVotes AGAINSTVotes ABSTAINEDBroker Non-Votes\n\n21,049,1011,4521540\n\nProposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.\n\nVotes FORVotes AGAINSTVotes ABSTAINEDBroker Non-Votes\n\n18,346,099300,2178762,403,515\n\nProposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.\n\n1 YEAR2 YEARS3 YEARSVotes ABSTAINEDBroker Non-Votes\n\n18,644,8819038875212,403,515\n\nBased on the foregoing votes, each of Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE was elected as a Class II director, Proposal 2 and Proposal 3 were approved, and shareholders recommended a one year frequency for future advisory votes to approve named executive officer compensation.\n\nBased on the foregoing voting results and consistent with the recommendation of the Board of Directors of the Company (the “Board”), the Board has determined to hold an advisory vote on the compensation of the Company’s named executive officers every year until the next advisory vote regarding the frequency of future advisory votes on the compensation of the Company’s named executive officers is submitted to the shareholders or the Board otherwise determines that a different frequency for such advisory votes is in the best interest of the Company and its shareholders.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nCRESCENT BIOPHARMA, INC.\n\nDate: June 3, 2026By:/s/ Joshua Brumm\n\nName:Joshua Brumm\n\nTitle:Chief Executive Officer"}